Modalités de prise en charge des neutropénies fébriles chez les patients traités pour une néoplasie solide dans le service d’urgence de cancérologie Gustave-Roussy et leurs impacts économiques

Borget, Isabelle; Antoun, Sami; Chachaty, Élisabeth; Gachot, Bertrand; Alibay, Arif; Palma, Mario Di; Merad, Mansouria

doi:10.1684/bdc.2014.1958

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2017, Teh et al [ 30 ] reported 2.65 times lower costs after applying an ambulatory strategy in low-risk patients compared to a comparable historic cohort in the same hospital. Finally, Borget et al [ 31 ] aimed to identify where the largest economic burden came from, comparing the standard hospital strategy versus outpatient treatment in hospital and ambulatory treatment outside of it, reporting successive decreases in costs in each setting.…”

Section: Resultsmentioning

confidence: 99%

Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systematic review

Forcano-Queralt,

Lemes-Quintana,

Orozco-Beltrán

2023

Support Care Cancer

View full text Add to dashboard Cite

Purpose Recent clinical practice guidelines have recommended ambulatory management of febrile neutropenia in patients with low risk of complications. Although some centers have begun developing management protocols for these patients, there appears to be a certain reluctance to implement them in clinical practice. Our aim is to evaluate the strengths and weaknesses of this strategy according to available evidence and to propose new lines of research. Methods Systematic review using a triple aim approach (efficacy, cost-effectiveness, and quality of life), drawing from literature in MEDLINE (PubMed), Embase, and Cochrane Library databases. The review includes studies that assess ambulatory management for efficacy, cost-efficiency, and quality of life. Results The search yielded 27 articles that met our inclusion criteria. Conclusion In conclusion, based on current evidence, ambulatory management of febrile neutropenia is safe, more cost-effective than inpatient care, and capable of improving quality of life in oncological patients with this complication. Ambulatory care seems to be an effective alternative to hospitalization in these patients.

show abstract

Section: Resultsmentioning

confidence: 99%